BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 17275507)

  • 21. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid.
    Uemura T; Schaefer E; Hollenbeak CS; Khan A; Kadry Z
    Transpl Int; 2011 Jul; 24(7):640-50. PubMed ID: 21429047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials.
    Tian JH; Wang X; Yang KH; Liu AP; Luo XF; Zhang J
    Transplant Proc; 2009 Nov; 41(9):3671-6. PubMed ID: 19917365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
    N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study.
    Oertel M; Sack U; Kohlhaw K; Lehmann I; Emmrich F; Berr F; Hauss J; Schwarz R
    Transpl Int; 2002 Oct; 15(9-10):463-71. PubMed ID: 12389078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are heart-lung transplant recipients protected from developing bronchiolitis obliterans syndrome?
    Moffatt-Bruce SD; Karamichalis J; Robbins RC; Whyte RI; Theodore J; Reitz BA
    Ann Thorac Surg; 2006 Jan; 81(1):286-91; discussion 291. PubMed ID: 16368382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of cytolytic therapy on bronchiolitis obliterans syndrome.
    Date H; Lynch JP; Sundaresan S; Patterson GA; Trulock EP
    J Heart Lung Transplant; 1998 Sep; 17(9):869-75. PubMed ID: 9773858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection.
    Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR
    Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction therapy with daclizumab in heart transplantation--how many doses?
    Ortiz V; Almenar L; Martínez-Dolz L; Zorio E; Chamorro C; Moro J; Agüero J; Rueda J; Arnau MA; Salvador A
    Transplant Proc; 2006 Oct; 38(8):2541-3. PubMed ID: 17097995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
    Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
    Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rabbit antithymocyte globulin. A 10-year experience in cardiac transplantation.
    Copeland JG; Icenogle TB; Williams RJ; Rosado LJ; Butman SM; Vasu MA; Sethi GK; McDonald AN; Klees E; Rhenman MJ
    J Thorac Cardiovasc Surg; 1990 May; 99(5):852-60. PubMed ID: 2329823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
    Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
    J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric liver transplantation with daclizumab induction.
    Heffron TG; Pillen T; Smallwood GA; Welch D; Oakley B; Romero R
    Transplantation; 2003 Jun; 75(12):2040-3. PubMed ID: 12829908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
    Hao WJ; Zong HT; Cui YS; Zhang Y
    Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Midterm results of a prospective randomized comparison of two different rabbit-antithymocyte globulin induction therapies after heart transplantation.
    De Santo LS; Della Corte A; Romano G; Amarelli C; Onorati F; Torella M; De Feo M; Marra C; Maiello C; Giannolo B; Casillo R; Ragone E; Grimaldi M; Utili R; Cotrufo M
    Transplant Proc; 2004 Apr; 36(3):631-7. PubMed ID: 15110616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
    Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation.
    Clinckart F; Bulpa P; Jamart J; Eucher P; Delaunois L; Evrard P
    Transplant Proc; 2009 Mar; 41(2):607-9. PubMed ID: 19328937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients.
    Wang D; Wu WZ; Yang SL; Chen JH; Tan JM
    Chin Med J (Engl); 2006 Oct; 119(20):1683-8. PubMed ID: 17097014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
    Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.